Immunoglobulin light chains: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 16: | Line 16: | ||
<span style="color:navy">'''Normal expression and function'''</span> | <span style="color:navy">'''Normal expression and function'''</span> | ||
The immunoglobulin molecule (with either kappa or lambda light chain) forms the antigen-recognising portion of the B-cell receptor. Normal mature B cells therefore express light chains which are formed during pro-B to pre-B cell development appearing at the surface and remaining expressed on the cell surface until plasma cell development (when the immunoglobulin molecules become internal contaned within cytoplasmic secretory vesicles). | |||
Revision as of 18:16, 27 May 2023
- Summary
- Immunoglobulin light chains are part of the B-cell receptor and can therefore be considered as a pan B-cell marker - expressed from late lymphoblast stage until plasma cell differentiation.
- Where cells express predomnantly kappa or lambda (light chain restriction) then clonality can be inferred.
Normal expression and function
The immunoglobulin molecule (with either kappa or lambda light chain) forms the antigen-recognising portion of the B-cell receptor. Normal mature B cells therefore express light chains which are formed during pro-B to pre-B cell development appearing at the surface and remaining expressed on the cell surface until plasma cell development (when the immunoglobulin molecules become internal contaned within cytoplasmic secretory vesicles).
Diagnostic role
- xxxxx
Other relevant information:
xxxxx
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
Expression in primitive cell types | |||||||
---|---|---|---|---|---|---|---|
AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
Expression in mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% | ? <5% 5-20% 20-40% 40-80% 80-100% |
Notes: xxxxx